|
°Ç°º¸Çè½É»çÆò°¡¿ø ½É»çÆò°¡¿¬±¸¼Ò(¼ÒÀå ±èÀ±)´Â ¿À´Â 19ÀÏ º»¿ø ´ë°´ç¿¡¼ Á¦27ȸ ½ÉÆòÆ÷·³À» °³ÃÖÇÑ´Ù.
À̹ø ½ÉÆòÆ÷·³Àº ¡®ÀÇ·á±â¼ú ±Þ¿© °áÁ¤¿¡ ´ëÇÑ ¿Ü±¹ °æÇè°ú ±³ÈÆ(Coverage Decision Making in Health Technology Assessment : Experiences and Lessons of Foreign Countries)¡¯À» ÁÖÁ¦·Î ¿Ü±¹ ¿¬ÀÚÀÇ ÁÖÁ¦¹ßÇ¥ ¹× ÁúÀÇÀÀ´ä Çü½ÄÀ¸·Î ÁøÇàµÈ´Ù.
ù ¹øÂ°·Î ¿µ±¹ NICEÀÇ ·Õ¼ÕÀÌ ¡®ÀÇ·á±â¼ú ±Þ¿©°áÁ¤¿¡ ´ëÇÑ ¿µ±¹ NICEÀÇ °æÇè°ú ±³ÈÆ(Using health technology assessment in coverage decision making: experiences and lessons from NICE)¡¯À» ¹ßÇ¥ÇÑ´Ù.
µÎ ¹øÂ°´Â ÀϺ» ±¹¸³º¸°ÇÀÇ·á°úÇпø ÈÄÄí´Ù¾¾°¡ ¡®ÀϺ»ÀÇ ÀǾàǰ °¡°Ý°áÁ¤ ¹× ÀÇ·á±â¼úÆò°¡(Drug Pricing and HTA in Japan)¡¯¸¦ ÁÖÁ¦·Î ¹ßÇ¥ÇÒ °èȹÀÌ´Ù.
¸¶Áö¸·À¸·Î ¿µ±¹ÀÇ °íµå¸¸Àº ¡®Ã³¹æ È¿À²¼º °³¼±¿¡ ´ëÇÑ À¯·´ °æÇè°ú ½Ã»çÁ¡(Initiatives across Europe to enhance prescribing efficiency to maintain universal coverage: findings and implications)¡¯¿¡ ´ëÇØ °¿¬ÇÑ´Ù.
|